Creating a new vaccine to improve protection against tuberculosis
Official title: Development of a novel adjuvanted Th1- and Th17-inducing subunit TB Vaccine
Funded at University of Chicago · NIH-10896905 · Data updated 2026-11-12
This study is working on a new tuberculosis vaccine that uses special ingredients to boost your immune system, and it aims to create a better option for fighting TB, with patients helping to test its safety and effectiveness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | March 1, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $472,273 |
| NIH project number | 5R61AI169071-03 |
| Project ID | NIH-10896905 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would be adults over 21 years old, particularly those at risk for tuberculosis or with latent TB infections.
✕Less likely to help
Patients who are not at risk for tuberculosis or those with active TB infections may not benefit from this research.
What this research studies
This research focuses on developing a novel vaccine for tuberculosis (TB) that incorporates new adjuvants to enhance the immune response. The approach aims to stimulate specific types of immune cells (Th1 and Th17) that are crucial for fighting TB infections. By optimizing these adjuvants and testing their effectiveness in generating a strong immune response, the researchers hope to create a more effective vaccine than the currently available options. Patients may be involved in trials to assess the safety and efficacy of this new vaccine.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against tuberculosis, potentially reducing the incidence and severity of the disease.
How similar studies have gone: Previous research has shown promise in using novel adjuvants to enhance vaccine efficacy, suggesting that this approach could lead to significant advancements in TB vaccination.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Khader, Shabaana a. — University of Chicago
- Study coordinator: Khader, Shabaana a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.